{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:25:35Z","timestamp":1767626735123,"version":"3.40.5"},"reference-count":45,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s251070","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T20:59:46Z","timestamp":1592513986000},"page":"317-325","source":"Crossref","is-referenced-by-count":7,"title":["<p>US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma<\/p>"],"prefix":"10.2147","volume":"Volume 12","author":[{"given":"Jan","family":"Bassali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian Gopal","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-4227","authenticated-orcid":true,"given":"James A","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-1149","authenticated-orcid":true,"given":"Deirdre","family":"Mladsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-6088","authenticated-orcid":true,"given":"Jyotsna","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"ref2","unstructured":"Surveillance, Epidemiology, and End Results (SEER). Program. Cancer stat facts: myeloma. 2016. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed November 27, 2018."},{"key":"ref3","unstructured":"Cancer facts & Figures 2019. Available from: http:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2019\/cancer-facts-and-figures-2019.pdf. Accessed October 30, 2019."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.02.007","volume":"112","author":"Sonneveld","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S2152265019320087","DOI":"10.1016\/j.clml.2019.09.621","author":"Mikhael","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1182\/blood-2018-99-115078","volume":"132","author":"Cornell","year":"2018","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"Pick","year":"2018","journal-title":"Eur J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"Usmani","year":"2016","journal-title":"The Oncologist"},{"key":"ref14","unstructured":"XPOVIO (selinexor) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212306s000lbl.pdf. Available from: Accessed July. 8, 2019."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1016\/j.clml.2018.07.149","volume":"18","author":"Jagannath","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.18553\/jmcp.2019.25.2.272","volume":"25","author":"Runyan","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.18553\/jmcp.2018.24.1.39","volume":"24","author":"Djatche","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health"},{"key":"ref23","unstructured":"The AMCP format for formulary submissions, version 3.1. A format for submission of clinical and economic evidence of pharmaceuticals in support of formulary consideration. December 2012. Available from: http:\/\/amcp.org\/practice-resources\/amcp-format-formulary-submisions.pdf. Accessed July 16, 2018.."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2017.1361035","volume":"59","author":"MacEwan","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref25","unstructured":"2017 National Population Projections Datasets. Available from: https:\/\/www.census.gov\/data\/datasets\/2017\/demo\/popproj\/2017-popproj.html. Accessed January 29, 2019."},{"key":"ref26","unstructured":"Karyopharm Therapeutics, Inc. Epidemiology presentation. Data on file. 2018a."},{"key":"ref27","unstructured":"Karyopharm Therapeutics, Inc. Updated MM Epidemiology Presentation based on Symphony claims analysis (2016-2018); FHAD (2011-2018); STORM recruitment; and market research. Data on file; 2019."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/pds.3927","volume":"25","author":"Cid Ruzafa","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"ref31","unstructured":"Cubanski J, Damico A, Neuman T. Medicare Part D: A first look at prescription drug plans in 2019. Available from: https:\/\/www.kff.org\/medicare\/issue-brief\/medicare-part-d-a-first-look-at-prescription-drug-plans-in-2019\/. Accessed February 1, 2019."},{"key":"ref32","unstructured":"Center for Medicare and Medicaid Services, Fast Facts. January 2019. Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/CMS-Fast-Facts\/index.html. Accessed May 18, 2020. 7, 2019."},{"key":"ref33","unstructured":"Selinexor Treatment of Refractory Myeloma (STORM). August 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02336815?term=NCT02336815&rank=1. Accessed November 21, 2018."},{"key":"ref34","unstructured":"Micromedex 2.0. Red Book Online. Thomson Reuters. Available from: https:\/\/www.micromedexsolutions.com. Accessed December 17, 2018.."},{"key":"ref35","unstructured":"Karyopharm Therapeutics, Inc. Email correspondence regarding pricing. Data on file. 2018c."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Mauskopf J, Earnshaw SR, Brogan AJ, Wolowacz S, Brodtkorb T-H Budget-Impact Analysis of Health Care Interventions: A Practical Guide; 2017.","DOI":"10.1007\/978-3-319-50482-7"},{"key":"ref37","unstructured":"Bureau of Economic Analysis, 2018: Table 2.4.4U. Price Indexes for Personal Consumption Expenditures by Type of Product. December 2018."},{"key":"ref38","unstructured":"Karyopharm Therapeutics, Inc. US Demand Estimation Presentation. Data on file, 2018d."},{"key":"ref39","unstructured":"Karyopharm Therapeutics, Inc. KCP-330-012 CSR. Data on file. 2018b."},{"key":"ref40","unstructured":"Patterns of Health Care Resource Use Required for Treatment of Each TEAE Based on Guidance from James A. Kaye, MD (Hematology, Oncology). DrPH, RTI Health Solutions."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1182\/blood.V128.22.3555.3555","volume":"128","author":"Shao","year":"2016","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.18553\/jmcp.2016.22.8.991","volume":"22","author":"Bloudek","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1182\/blood.V128.22.2363.2363","volume":"128","author":"Potluri","year":"2016","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.18553\/jmcp.2017.23.10-a.s1","author":"Hollmann","year":"2017","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=58995","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=58995","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T20:59:54Z","timestamp":1592513994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/us-budget-impact-model-for-selinexor-in-relapsed-or-refractory-multipl-peer-reviewed-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":45,"URL":"https:\/\/doi.org\/10.2147\/ceor.s251070","relation":{},"ISSN":["1178-6981"],"issn-type":[{"type":"electronic","value":"1178-6981"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}